HCV
64
10
13
31
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
12 trials with published results (19%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.1%
2 terminated out of 64 trials
93.9%
+7.4% vs benchmark
16%
10 trials in Phase 3/4
39%
12 of 31 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 31 completed trials
Clinical Trials (64)
National Rapid TLC: Testing and Linkage to Care
The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City
Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East Austria
Integrated HIV Prevention and HCV Care for PWID
Appalachian Partnership to Reduce Disparities (Aim 2)
A Setting Focus Overdose Prevention Intervention
Simplified HCV Integrated Management Model in Methadone Clinics in Ukraine
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
HIV/HBV/HCV Triple Screening in Primary Care
Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland
The South-East Asian Transgender Health Cohort
Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide
Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients
Facilitated Telemedicine in the Catholic Health System
Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis)
HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Community Intervention to Eliminate HCV Among People Who Use Drugs.
Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada
Hepatitis C Treatment in Probation and Parole Office